Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.78 |
| ▸ | TYR | P14679 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.44 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.44 |
| ▸ | TST | Q16762 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MANBA | O00462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ascorbic Acid SCHEMBL11127598 | 0.94 | MAPT (0.69) | MAPTLMNAL3MBTL1TYRTDP1 | |
| Ascorbic Acid SCHEMBL6937259 | 0.94 | MAPT (0.83) | MAPTLMNAL3MBTL1TYRTDP1 | |
| Ascorbic Acid SCHEMBL4146647 | 0.90 | MAPT (0.96) | MAPTLMNAL3MBTL1TYRTDP1 | |
| Ascorbic Acid SCHEMBL30461160 | 0.90 | MAPT (0.96) | MAPTLMNAL3MBTL1TYRTDP1 | |
| Ascorbic Acid SCHEMBL22589022 | 0.90 | MAPT (0.96) | MAPTLMNAL3MBTL1TYRTDP1 | |
| Ascorbic Acid SCHEMBL183332 | 0.89 | MAPT (0.81) | MAPTLMNAL3MBTL1TYRTDP1 | |
| Ascorbic Acid SCHEMBL31346822 | 0.89 | MAPT (0.81) | MAPTLMNAL3MBTL1TYRTDP1 | |
| Ascorbic Acid SCHEMBL5879339 | 0.89 | MAPT (0.93) | MAPTLMNAL3MBTL1TYRTDP1 | |
| Ascorbic Acid SCHEMBL2096728 | 0.89 | MAPT (0.93) | MAPTLMNAL3MBTL1TYRTDP1 | |
| Ascorbic Acid SCHEMBL11981759 | 0.88 | MAPT (1.00) | MAPTLMNAL3MBTL1TYRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106793970-B | Nanoparring agents for diagnosis and therapy and processing thereof | 罗得岛医院 | 2021-07-30 | — | — | CN | disclosed |
| US-10675353-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2020-03-05 | — | — | US | disclosed |
| US-9926357-B2 | BMP-7 peptides and methods of use | LIFENET HEALTH (US) | 2018-03-27 | — | — | US | disclosed |
| CN-106793970-A | Nanoparring agents for diagnosis and therapy and processing thereof | 罗得岛医院 | 2017-05-31 | — | — | CN | disclosed |
| US-20130196909-A1 | BMP-7 Peptides and Methods of Use | LIFENET HEALTH (US) | 2013-08-01 | — | — | US | disclosed |
| EP-1986612-A2 | STABILIZED COMPOSITIONS OF PROTEINS HAVING A FREE THIOL MOIETY | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007092829-A2 | STABILIZED COMPOSITIONS OF PROTEINS HAVING A FREE THIOL MOIETY | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070042423-A1 | Diagnostics and therapeutics for diseases associated with arginyl aminopeptidase rnpep-like (rnpep-like) | BAYER HEALTHCARE AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-6770745-B2 | ANTIBODIES WHICH SPECIFICALLY BIND TO THE GC CHAIN OF CYTOKINE RECEPTORS | BIOGEN IDEC MA INC. | 2004-08-03 | — | — | US | disclosed |
| US-20020028202-A1 | Common gamma chain blocking agents | BIOGEN MA INC. | 2002-03-07 | — | — | US | disclosed |
| US-6323027-B1 | Common gamma chain monoclonal antibody blocking agents | BIOGEN, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-0918858-A1 | COMMON GAMMA CHAIN BLOCKING AGENTS | BIOGEN, INC. (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997043416-A1 | COMMON GAMMA CHAIN BLOCKING AGENTS | BIOGEN, INC. (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028202-A1 | Common gamma chain blocking agents | FCGR2A, FCGR3B, FCGR1A | MAPT 4214/4885LMNA 3864/4885L3MBTL1 2705/4885 |
| US-10675353-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | MAPT 3436/4885LMNA 1034/4885L3MBTL1 1995/4885 |
| US-20200069808-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | FCGRT, EPOR, MCL1 | MAPT 3436/4885LMNA 1034/4885L3MBTL1 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.